نتایج جستجو برای: lymphoma therapy

تعداد نتایج: 741717  

2014
Jun-Yeong Seo Kee-Yong Ha Min-Up Kim Yoon-Chung Kim Young-Hoon Kim

INTRODUCTION Although non-Hodgkin's lymphoma is one of the most common and frequently fatal of the acquired immune deficiency syndrome-defining illnesses, survival has improved significantly since the introduction of antiretroviral therapy. Patients with spinal cord compression resulting from non-Hodgkin's lymphoma present with clinically acute or rapidly progressive neurologic deficits. The pu...

2014
Lidia Gil Maciej Kazmierczak Renata Kroll-Balcerzak Mieczyslaw Komarnicki

Recently, bendamustine has become an important agent in the treatment for patients with lymphoid malignancies. Although the drug has received approval for second-line therapy in indolent lymphoma, a growing body of evidence suggests its efficacy and safety in first-line use. The results of randomised and observational studies with bendamustine as front-line therapy in non-Hodgkin lymphoma (NHL)...

Journal: :Haematologica 2009
Mark Bower Martin Fisher Teresa Hill Iain Reeves John Walsh Chloe Orkin Andrew N Phillips Loveleen Bansi Richard Gilson Philippa Easterbrook Margaret Johnson Brian Gazzard Clifford Leen Deenan Pillay Achim Schwenk Jane Anderson Kholoud Porter Mark Gompels Caroline A Sabin

Since the introduction of highly active antiretroviral therapy, there has been a decline in the incidence of non-Hodgkin's lymphoma among HIV-infected individuals. We described trends in the incidence of systemic non-Hodgkin's lymphoma in the UK CHIC Study from 1996-2006 and evaluated the association between immunosuppression and development of systemic non-Hodgkin's lymphoma: 286/23,155 (1.2%)...

Journal: :Cancer research 1988
T Y Basham M A Palladino C C Badger I D Bernstein R Levy T C Merigan

Two murine models, C3H 38C13 B-cell lymphoma and AKR SL2 T-cell lymphoma were used to determine the efficacy of three different interferon preparations, recombinant human hybrid interferon-alpha A/D, recombinant murine interferon (rMIFN)-gamma, and natural MIFN-alpha/beta (greater than or equal to 85% beta), alone and in combination with tumor specific and nonspecific monoclonal antibody therap...

2017
Hirokazu Nagai Reiji Fukano Masahiro Sekimizu Akiko Kada Akiko M. Saito Ryuta Asada Tetsuya Mori

Currently, a standard therapy has not been established for recurrent or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. While there are many treatment options, such as hematopoietic stem cell transplantation, patients with resistant disease to conventional chemotherapies have particularly poor prognosis. There is urgent need to develop new drugs because of the lac...

Journal: :Oncology Letters 2023

Primary central nervous system lymphoma (PCNSL) is an extranodal type of lymphoma, which treated with methotrexate (MTX)‑based induction therapy. Although PCNSL a hematological malignancy, patients may be at neurosurgery or hematology/oncology departments; however, the outcomes treatment have not been compared between these two departments. The present study 26 newly diagnosed that were Departm...

2012
YL Kwong

The incidence of follicular lymphoma, a low-grade malignant B-cell lymphoma, is increasing in most Asian populations. Follicular lymphoma is generally considered to be indolent with a life expectancy of approximately 10 to 14 years. However, it is characterised by repeated relapse, and disease progression typically occurs 3 to 5 years after initial treatment. Rituximab, a monoclonal antibody, d...

2016
Michael D. Chang Merry-Jennifer Markham Xiuli Liu

The link between immunosuppressive therapy and increased lymphoma risk is well established in patients with solid organ transplantation. Epstein-Barr virus-positive (EBV) diffuse large B-cell lymphoma (DLBCL) is known to be a complication in patients receiving methotrexate for rheumatoid arthritis, and the risk of lymphoma in inflammatory bowel disease (IBD) has raised concerns regarding the ly...

2006
Teresa Y. Basham Michael A. Palladino Christopher C. Badger Irwin D. Bernstein Ronald Levy Thomas C. Merigan

Two murine models, C3H 38C13 B-cell lymphoma and AKR SL2 I cell lymphoma were used to determine the efficacy of three different Interferon preparations, recombinant human hybrid interferon-a A/D, recombinant murine Interferon (rMIFN)-7, and natural MIFN-a//3 (>85% ß), alone and in combination with tumor specific and nonspecific monoclonal antibody therapy. All three Interferon preparations hav...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2006
S J Proctor J Wilkinson

In Hodgkin's lymphoma therapy, there remain areas of extreme difficulty. This article briefly explores these areas and provides evidence that risk-related therapy and web-based data collection programmes can facilitate progress. Unpublished data from the northern region of the UK suggest that risk-based therapy among poor-prognosis Hodgkin's lymphoma patients aged 15-19 years is improving outco...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید